The DEEP project has received research funding from the European Union under the 7th Framework Programme

agranulocytosis | DEEP Project

Management of agranulocytosis

Febbraio 10, 2016
Comments off

Severe Neutropenia/Agranulocytosis is a possible serious adverse event during treatment with the IMP. As agranulocytosis is a sudden and idiosyncratic adverse event, we suggest you to keep your centre supplied with supportive therapy (antibiotic therapy and granulocyte colony stimulating factor) and make sure […]

Read more →